Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME

Diabetes Research and Clinical Practice

Volumn 121, Issue , 2016, Pages 204-214

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Blood pressure; Diuretic; Empagliflozin; Hypertension; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CANAGLIFLOZIN; CAPTOPRIL; DAPAGLIFLOZIN; DIURETIC AGENT; EMPAGLIFLOZIN; ENALAPRIL; EPLERENONE; ERTUGLIFLOZIN; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IPRAGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; CONGESTIVE HEART FAILURE; DIABETIC PATIENT; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RISK REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG EFFECTS; META ANALYSIS; MORTALITY; PATHOPHYSIOLOGY;

BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84991665527     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.09.016     Document Type: Review

References (78)

1. [1] Ferrannini, E., Cushman, W.C., Diabetes and hypertension: the bad companions. Lancet 380 (2012), 601–610.
2. [2] Blood Pressure Lowering Treatment Trialists C, Sundstrom, J., Arima, H., Woodward, M., Jackson, R., Karmali, K., Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384 (2014), 591–598.
3. [3] Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A.D., Denaxas, S., et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383 (2014), 1899–1911.
4. [4] UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998), 703–713.
5. [5] UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet 352 (1998), 854–865.
6. [6] Heart Outcomes Prevention Evaluation Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000), 253–259.
7. [7] Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
8. [8] Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
9. [9] Ettehad, D., Emdin, C.A., Kiran, A., Anderson, S.G., Callender, T., Emberson, J., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
10. [10] Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
11. [11] Kintscher, U., Benefit of blood pressure control in diabetic patients. Curr Hypertens Rep, 17, 2015, 50.
12. [12] Arguedas, J.A., Leiva, V., Wright, J.M., Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev, 10, 2013 CD008277.
13. [13] Esler, M., SPRINT, or false start, toward a lower universal treated blood pressure target in hypertension. Hypertension 67 (2016), 266–267.
14. [14] Cryer, M.J., Horani, T., DiPette, D.J., Diabetes and hypertension: a comparative review of current guidelines. J Clin Hypertens (Greenwich) 18 (2016), 95–100.
15. [15] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
16. [16] Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
17. [17] Schernthaner, G., Schernthaner-Reiter, M.H., Schernthaner, G.H., EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in type 2 diabetes mellitus. Clin Ther 38 (2016), 1288–1298.
18. [18] Ryden, L., Shahim, B., Mellbin, L., Clinical implications of cardiovascular outcome trials in type 2 diabetes: from DCCT to EMPA-REG. Clin Ther 38 (2016), 1279–1287.
19. [19] Scheen, A.J., Cardiovascular effects of gliptins. Nat Rev Cardiol 10 (2013), 73–84.
20. [20] Scheen, A.J., Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14 (2015), 505–524.
21. [21] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
22. [22] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
23. [23] Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
24. [24] Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes Vasc Dis Res 12 (2015), 90–100.
25. [25] Ghosh, R.K., Bandyopadhyay, D., Hajra, A., Biswas, M., Gupta, A., Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. Int J Cardiol 212 (2016), 29–36.
26. [26] Oliva, R.V., Bakris, G.L., Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8 (2014), 330–339.
27. [27] Maliha, G., Townsend, R.R., SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 9 (2015), 48–53.
28. [28] Imprialos, K.P., Sarafidis, P.A., Karagiannis, A.I., Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?. J Hypertens 33 (2015), 2185–2197.
29. [29] Baker, W.L., Smyth, L.R., Riche, D.M., Bourret, E.M., Chamberlin, K.W., White, W.B., Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens, 8(262–275), 2014, e9.
30. [30] Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37 (2016), 1526–1534.
31. [31] Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab 42 (2016), 71–76.
32. [32] DeFronzo, R.A., The EMPA-REG study: What has it told us? A diabetologist's perspective. J Diabetes Complications 30 (2016), 1–2.
33. [33] Rajasekeran, H., Lytvyn, Y., Cherney, D.Z., Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 89 (2016), 524–526.
34. [34] Kimura, G., Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens 10 (2016), 271–278.
35. [35] Takeuchi, T., Dohi, K., Omori, T., Moriwaki, K., Sato, Y., Nakamori, S., et al. Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol 201 (2015), 1–3.
36. [36] McMurray, J., EMPA-REG - the “diuretic hypothesis”. J Diabetes Complications 30 (2016), 3–4.
37. [37] Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
38. [38] Scheen, A.J., Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: comparison with classic diuretics. Diabetes Metab 42 (2016), 224–233.
39. [39] John, M., Empagliflozin: not just a glorified diuretic. Indian J Endocrinol Metab 20 (2016), 154–156.
40. [40] Zaccardi, F., Webb, D.R., Htike, Z.Z., Youssef, D., Khunti, K., Davies, M.J., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 18 (2016), 783–794.
41. [41] Townsend, R.R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich) 18 (2016), 43–52.
42. [42] Weir, M.R., Januszewicz, A., Gilbert, R.E., Vijapurkar, U., Kline, I., Fung, A., et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 16 (2014), 875–882.
43. [43] Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
44. [44] Weber, M.A., Mansfield, T.A., Cain, V.A., Iqbal, N., Parikh, S., Ptaszynska, A., Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4 (2016), 211–220.
45. [45] Sjostrom, C.D., Johansson, P., Ptaszynska, A., List, J., Johnsson, E., Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diabetes Vasc Dis Res 12 (2015), 352–358.
46. [46] Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U.C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38 (2015), 420–428.
47. [47] Amin, N.B., Wang, X., Mitchell, J.R., Lee, D.S., Nucci, G., Rusnak, J.M., Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab 17 (2015), 805–808.
48. [48] Tamura, K., Wakui, H., Azushima, K., Uneda, K., Umemura, S., Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes. Hypertens Res 39 (2016), 396–398.
49. [49] Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
50. [50] Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
51. [51] Heerspink, H.J., Johnsson, E., Gause-Nilsson, I., Cain, V.A., Sjostrom, C.D., Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 18 (2016), 590–597.
52. [52] Scheen, A.J., Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
53. [53] Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
54. [54] Emdin, C.A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A., Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
55. [55] Xie, X.X., Liu, P., Wan, F.Y., Lin, S.G., Zhong, W.L., Yuan, Z.K., et al. Blood pressure lowering and stroke events in type 2 diabetes: a network meta-analysis of randomized controlled trials. Int J Cardiol 208 (2016), 141–146.
56. [56] Brunstrom, M., Carlberg, B., Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, 2016, i717.
57. [57] Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
58. [58] ACCORD Study Group, Cushman, W.C., Evans, G.W., Byington, R.P., Goff, D.C. Jr., Grimm, R.H. Jr., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
59. [59] Weber, M.A., Bloch, M., Bakris, G.L., Weir, M.R., Zappe, D.H., Dahlof, B., et al. Cardiovascular outcomes according to systolic blood pressure in patients with and without diabetes: an ACCOMPLISH substudy. J Clin Hypertens (Greenwich) 18 (2016), 299–307.
60. [60] SPRINT Research Group, Wright, J.T. Jr., Williamson, J.D., Whelton, P.K., Snyder, J.K., Sink, K.M., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
61. [61] Turnbull, F., Neal, B., Algert, C., Chalmers, J., Chapman, N., Cutler, J., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005), 1410–1419.
62. [62] Bangalore, S., Kumar, S., Lobach, I., Messerli, F.H., Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 123 (2011), 2799–2810 [9 p following 810].
63. [63] Lonn, E.M., Bosch, J., Lopez-Jaramillo, P., Zhu, J., Liu, L., Pais, P., et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
64. [64] Psaty, B.M., Lumley, T., Furberg, C.D., Schellenbaum, G., Pahor, M., Alderman, M.H., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003), 2534–2544.
65. [65] Davis, B.R., Piller, L.B., Cutler, J.A., Furberg, C., Dunn, K., Franklin, S., et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-lowering treatment to prevent heart attack trial. Circulation 113 (2006), 2201–2210.
66. [66] Grossman, E., Verdecchia, P., Shamiss, A., Angeli, F., Reboldi, G., Diuretic treatment of hypertension. Diabetes Care 34:Suppl. 2 (2011), S313–S319.
67. [67] Sweileh, W.M., Target blood pressure attainment in diabetic hypertensive patients: need for more diuretics?. Int J Clin Pharmacol Ther 47 (2009), 434–438.
68. [68] Chen, P., Chaugai, S., Zhao, F., Wang, D.W., Cardioprotective effect of thiazide-like diuretics: a meta-analysis. Am J Hypertens 28 (2015), 1453–1463.
69. [69] Olde Engberink, R.H., Frenkel, W.J., van den Bogaard, B., Brewster, L.M., Vogt, L., van den Born, B.J., Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 65 (2015), 1033–1040.
70. [70] Lievre, M., Gueyffier, F., Ekbom, T., Fagard, R., Cutler, J., Schron, E., et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. Diabetes Care 23:Suppl. 2 (2000), B65–B71.
71. [71] Remonti, L.R., Dias, S., Leitao, C.B., Kramer, C.K., Klassman, L.P., Welton, N.J., et al. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes-Network meta-analysis of randomized trials. J Diabetes Complications 30 (2016), 1192–1200.
72. [72] Takahashi, S., Katada, J., Daida, H., Kitamura, F., Yokoyama, K., Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens 30 (2016), 534–542.
73. [73] Chen, M.D., Dong, S.S., Cai, N.Y., Fan, M.D., Gu, S.P., Zheng, J.J., et al. Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. BMC Cardiovasc Disord, 16, 2016, 28.
74. [74] Pelliccia, F., Patti, G., Rosano, G., Greco, C., Gaudio, C., Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol 177 (2014), 219–228.
75. [75] Wu, J.H., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundstrom, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
76. [76] Monami, M., Dicembrini, I., Mannucci, E., Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol, 2016 [Epub ahead of print].
77. [77] Muskiet, M.H., van Raalte, D.H., van Bommel, E., Smits, M.M., Tonneijck, L., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3 (2015), 928–929.
78. [78] Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.